Mutabilis is a biotechnology company focused on the development of novel chemical entities, from biological targets to the end of Phase I, to treat MDR Gram-negative bacterial infections. Mutabilis’ team has a unique expertise in diazabicyclooctane chemistry and its applications in the discovery of novel antibacterials and beta-lactamase inhibitors, inherited from the former Novexel company that contributed to the development of Avibactam. With outstanding stability to hydrolysis by serine- and metallo-beta-lactamases, diazabicyclooctane derivatives are particularly promising to address the most difficult infections, namely those that are resistant to carbapenems. Mutabilis is based in Romainville, near Paris, and has 27 employees, most of whom are dedicated to research and development.